查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1424044

勝□和寡核甘酸 CDMO 市場、份額、規模、趨勢、行業分析報告：按產品、按服務、按最終用戶、按地區、按細分市場、預測，2024-2032 年

Peptide and Oligonucleotide CDMO Market Share, Size, Trends, Industry Analysis Report, By Product (Peptides, Oligonucleotides); By Service; By End User; By Region; Segment Forecast, 2024- 2032
出版日期: | 出版商: Polaris Market Research | 英文 118 Pages | 商品交期: 最快1-2個工作天內

價格

根據Polaris Market Research的最新研究，預計到2032年，全球勝□和寡核甘酸CDMO市場規模將達到46.4657億美元。 該研究報告提供了對當前市場動態的詳細洞察，並對未來市場成長進行了分析。

勝□和寡核甘酸 CDMO 在勝□和寡核甘酸的複雜合成中提供高度專業的專業知識並保證精度。 CDMO 憑藉優化的流程和規模經濟提供具有成本效益的解決方案。 我們最先進的工廠遵循嚴格的品質標準和法規合規性，並配備先進的技術。 製造的可擴展性允許靈活適應藥物開發不同階段的不同需求。

勝□和寡核甘酸合約開發涉及客戶和 CDMO 之間的密切合作。 在專案規劃階段，雙方徹底確定目標、範圍和進度，並全面了解客戶的需求。 後續階段包括生物分子陣列的複雜設計和最佳化、嚴格的可擴展性製程開發以及有效分析方法的建立。 在整個製造過程中嚴格採用符合監管合規標準的品質控制措施。 技術轉移、詳細的專案完成報告以及持續改進的舉措凸顯了我們為這些關鍵生物分子提供高品質、可重複的製造流程的承諾。

勝□和寡核甘酸 CDMO 製造組織透過提供客製化的合成解決方案為研究機構服務。 這些公司在各種應用領域擁有專業知識，包括藥物發現和生物標記開發。 研究機構受惠於 CDMO 推動的無縫放大流程，確保分子的持續供應。 CDMO利用尖端技術，為研究機構提供精密實驗的尖端方法。

對法規遵循的支持提高了研究計畫的可信度，尤其是轉化應用。 合作夥伴關係促進協同效應，CDMO 為研究活動提供技術見解和創新解決方案。 分析服務確保合成分子的可靠性，靈活的服務模式適應動態專案的需求。 專案設計期間的諮詢優化了合成策略，我們對及時交付和成本效率的承諾確保了向研究機構持續供應材料。

勝□和寡核甘酸 CDMO 市場報告亮點

2023年，由於生物製藥應用的增加、診斷的進步和治療的進步，勝□領域佔據了很大的市場份額。

2023 年，由於外包專業知識、客製化生產和成本效率，合約製造業佔據了重要的市場份額。

2023 年，由於治療開發和簡化開發流程的專業服務需求不斷增長，生物製藥公司部門佔據了重要的市場收入份額。

2023 年，由於個人化醫療需求增加、研發活動增加和技術進步，北美地區佔據了最大的收入份額。

市場競爭激烈，市場參與者遍佈全球，包括 Bachem Group、CordenPharma、Creative Peptides、EUROAPI、Merck KGaA 和 PolyPeptide Group。

目錄

第一章簡介

第 2 章執行摘要

第三章研究方法

第四章全球多勝□與寡核甘酸 CDMO 市場洞察

  • 勝□和寡核甘酸 CDMO 市場 - 最終用戶快照
  • 多□和寡核甘酸 CDMO 市場動態
    • 推動者和機會
      • 對智慧型裝置連接和無縫整合的需求日益增長
      • 隨著全球環保意識的增強和對永續產品的需求，環保型勝□和寡核甘酸 CDMO 正在快速成長。
    • 抑制因素和挑戰
      • 勝□和寡核甘酸 CDMO 的高成本限制了市場成長
  • PESTEL 分析
  • 勝□和寡核甘酸 CDMO 市場的最終用戶趨勢
  • 價值鏈分析
  • COVID-19 感染的影響分析

第五章全球勝□與寡核甘酸 CDMO 市場（按產品）

  • 主要發現
  • 簡介
  • 勝□
  • 寡核甘酸

第 6 章全球勝□和寡核甘酸 CDMO 市場（按服務）

  • 主要發現
  • 簡介
  • 合約開發
  • 合約製造

第 7 章全球勝□與寡核甘酸 CDMO 市場（依最終使用者）

  • 主要發現
  • 簡介
  • 生物製藥公司
  • 製藥公司
  • 研究院
  • 學術和政府機構
  • 其他

第 8 章全球勝□與寡核甘酸 CDMO 市場（按地區）

  • 主要發現
  • 簡介
    • 2019-2032 年按地區劃分的勝□和寡核甘酸 CDMO 市場評估
  • 勝□和寡核甘酸 CDMO 市場 - 北美
    • 北美：勝□和寡核甘酸 CDMO 市場（按產品），2019-2032 年
    • 北美：勝□和寡核甘酸 CDMO 市場，按最終用戶劃分，2019-2032 年
    • 北美：2019-2032 年勝□和寡核甘酸 CDMO 市場（按服務劃分）
    • 勝□和寡核甘酸 CDMO 市場 - 美國
    • 勝□和寡核甘酸 CDMO 市場 - 加拿大
  • 勝□和寡核甘酸 CDMO 市場 - 歐洲
    • 歐洲：勝□和寡核甘酸 CDMO 市場（按產品），2019-2032 年
    • 歐洲：勝□和寡核甘酸 CDMO 市場，按最終用戶劃分，2019-2032 年
    • 歐洲：勝□和寡核甘酸 CDMO 市場，按服務分類，2019-2032 年
    • 勝□與寡核甘酸 CDMO 市場 - 英國
    • 勝□與寡核甘酸 CDMO 市場 - 法國
    • 勝□與寡核甘酸 CDMO 市場 - 德國
    • 勝□和寡核甘酸 CDMO 市場 - 義大利
    • 多勝□與寡核甘酸 CDMO 市場 - 西班牙
    • 勝□和寡核甘酸 CDMO 市場 - 荷蘭
    • 勝□和寡核甘酸 CDMO 市場 - 俄羅斯
  • 勝□和寡核甘酸 CDMO 市場 - 亞太地區
    • 亞太地區：勝□和寡核甘酸 CDMO 市場（按產品），2019-2032 年
    • 亞太地區：勝□和寡核甘酸 CDMO 市場，按最終用戶劃分，2019-2032 年
    • 亞太地區：勝□和寡核甘酸 CDMO 市場，按服務劃分，2019-2032 年
    • 多□和寡核甘酸 CDMO 市場 - 中國
    • 勝□和寡核甘酸 CDMO 市場 - 印度
    • 勝□和寡核甘酸 CDMO 市場 - 馬來西亞
    • 勝□與寡核甘酸 CDMO 市場 - 日本
    • 多□和寡核甘酸 CDMO 市場 - 印度尼西亞
    • 勝□和寡核甘酸 CDMO 市場 - 韓國
  • 多□和寡核甘酸 CDMO 市場 - 中東和非洲
    • 中東和非洲：勝□和寡核甘酸 CDMO 市場（按產品），2019-2032 年
    • 中東和非洲：勝□和寡核甘酸 CDMO 市場，按最終用戶劃分，2019-2032 年
    • 中東和非洲：勝□和寡核甘酸 CDMO 市場，按服務劃分，2019-2032 年
    • 多□和寡核甘酸 CDMO 市場 - 沙烏地阿拉伯
    • 勝□和寡核甘酸 CDMO 市場 - 阿聯酋
    • 勝□和寡核甘酸 CDMO 市場 - 以色列
    • 勝□和寡核甘酸 CDMO 市場 - 南非
  • 勝□與寡核甘酸 CDMO 市場 - 拉丁美洲
    • 拉丁美洲：勝□和寡核甘酸 CDMO 市場（按產品），2019-2032 年
    • 拉丁美洲：勝□和寡核甘酸 CDMO 市場，按最終用戶劃分，2019-2032 年
    • 拉丁美洲：勝□和寡核甘酸 CDMO 市場，按服務劃分，2019-2032 年
    • 勝□和寡核甘酸 CDMO 市場 - 墨西哥
    • 勝□和寡核甘酸 CDMO 市場 - 巴西
    • 勝□和寡核甘酸 CDMO 市場 - 阿根廷

第九章競爭態勢

  • 擴張與收購分析
    • 放大
    • 收購
  • 夥伴關係/協作/協議/揭露

第十章公司簡介

  • Aurigene Pharmaceutical Services Ltd.
  • Bachem Group
  • CordenPharma
  • Creative Peptides
  • Curia Global, Inc.
  • EUROAPI
  • Genscript Biotech Corporation
  • Lonza Group
  • Merck KGaA
  • PolyPeptide Group
  • Senn Chemicals AG
  • STA Pharmaceutical Co. Ltd.
  • Sylentis, S.A.
  • Thermo Fisher Scientific Inc.
  • Wuxi AppTec
Product Code: PM4342

The global Peptide and Oligonucleotide CDMO market size is expected to reach USD 4,646.57 million by 2032, according to a new study by Polaris Market Research. The report "Peptide and Oligonucleotide CDMO Market Share, Size, Trends, Industry Analysis Report, By Product (Peptides, Oligonucleotides); By Service; By End User; By Region; Segment Forecast, 2024- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Peptide and Oligonucleotide Contract Development and Manufacturing Organizations (CDMOs) offer highly specialized expertise in the intricate synthesis of peptides and oligonucleotides, ensuring precision. CDMOs offer cost-efficient solutions through optimized processes and economies of scale. Their state-of-the-art facilities adhere to rigorous quality standards and regulatory compliance, equipped with advanced technologies. Scalability in manufacturing allows for flexible adaptation to varying demands during different drug development phases.

Initiating the contract development for peptides and oligonucleotides involves a thorough collaborative endeavor between clients and CDMOs. In the project planning phase, both parties meticulously define objectives, scope, and timelines, ensuring a comprehensive understanding of client requirements. Subsequent stages encompass the intricate design and optimization of biomolecular sequences, rigorous process development for scalability, and the establishment of validated analytical methods. Quality control measures, aligned with regulatory compliance standards, are meticulously applied throughout manufacturing. Technology transfer, detailed project completion reports, and ongoing initiatives for continuous improvement underline the commitment to delivering high-quality, reproducible manufacturing processes for these essential biomolecules.

Peptide and oligonucleotide contract development and manufacturing organizations cater to research institutes by delivering tailored synthesis solutions. These entities bring specialized expertise across diverse applications, including drug discovery and biomarker development. Research institutes benefit from seamless scale-up processes facilitated by CDMOs, ensuring consistent molecule supply. CDMOs leverage state-of-the-art technologies, providing research institutions access to cutting-edge methodologies for precise experimentation.

Regulatory compliance support enhances the credibility of research projects, especially those with translational applications. Collaborative partnerships foster synergy, with CDMOs contributing technical insights and innovative solutions to research endeavors. Analytical services ensure the reliability of synthesized molecules, and flexible service models accommodate dynamic project needs. Consultation during project design optimizes synthesis strategies, and a commitment to timely delivery and cost efficiency ensures uninterrupted material supply for research institutes.

Peptide and Oligonucleotide CDMO Market Report Highlights

In 2023, the peptides segment accounted for substantial market share owing to rise in biopharmaceutical applications, diagnostic advancements, and therapeutic advancements.

In 2023, contract manufacturing segment accounted for significant market share due to outsourcing expertise, customized production, and cost efficiency.

In 2023, the biopharmaceutical companies segment held significant market revenue share due to greater demand for specialized services for therapeutic development, and streamlining of development processes.

In 2023, North America accounted for the largest revenue share due to rise in demand for personalized medicine, increased R&D activities, and technological advancements.

The market is highly competitive owing to the existence of market players with a global presence, including Bachem Group, CordenPharma, Creative Peptides, EUROAPI, Merck KGaA, and PolyPeptide Group among others.

Polaris Market Research has segmented the Peptide and Oligonucleotide CDMO market report based on product, service, end user, and region:

Peptide and Oligonucleotide CDMO, Product Outlook (Revenue - USD Million, 2019 - 2032)

  • Peptides
  • Oligonucleotides

Peptide and Oligonucleotide CDMO, Service Outlook (Revenue - USD Million, 2019 - 2032)

  • Contract Development
  • Contract Manufacturing

Peptide and Oligonucleotide CDMO, End User Outlook (Revenue - USD Million, 2019 - 2032)

  • Biopharmaceutical Companies
  • Pharmaceutical Companies
  • Research Institutes
  • Academic and Government Organizations
  • Others

Peptide and Oligonucleotide CDMO, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • France
  • Germany
  • UK
  • Italy
  • Netherlands
  • Spain
  • Russia
  • Asia Pacific
  • Japan
  • China
  • India
  • Malaysia
  • Indonesia
  • South Korea
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Peptide and Oligonucleotide CDMO Market Insights

  • 4.1. Peptide and Oligonucleotide CDMO Market - End User Snapshot
  • 4.2. Peptide and Oligonucleotide CDMO Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Growing need for connectivity and seamless integration with smart devices
      • 4.2.1.2. Rising environmental consciousness and the demand for sustainable products worldwide are driving the growth of eco-friendly Peptide and Oligonucleotide CDMO at rapid pace.
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of Peptide and Oligonucleotide CDMO limit the market growth
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Peptide and Oligonucleotide CDMO Market End User Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Peptide and Oligonucleotide CDMO Market, by Product

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • 5.3. Peptides
    • 5.3.1. Global Peptide and Oligonucleotide CDMO Market, by Peptides, by Region, 2019-2032 (USD Million)
  • 5.4. Oligonucleotides
    • 5.4.1. Global Peptide and Oligonucleotide CDMO Market, by Oligonucleotides, by Region, 2019-2032 (USD Million)

6. Global Peptide and Oligonucleotide CDMO Market, by Service

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • 6.3. Contract Development
    • 6.3.1. Global Peptide and Oligonucleotide CDMO Market, by Contract Development, by Region, 2019-2032 (USD Million)
  • 6.4. Contract Manufacturing
    • 6.4.1. Global Peptide and Oligonucleotide CDMO Market, by Contract Manufacturing, by Region, 2019-2032 (USD Million)

7. Global Peptide and Oligonucleotide CDMO Market, by End User

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • 7.3. Biopharmaceutical Companies
    • 7.3.1. Global Peptide and Oligonucleotide CDMO Market, by Biopharmaceutical Companies, By Region, 2019-2032 (USD Million)
  • 7.4. Pharmaceutical Companies
    • 7.4.1. Global Peptide and Oligonucleotide CDMO Market, by Pharmaceutical Companies, By Region, 2019-2032 (USD Million)
  • 7.5. Research Institutes
    • 7.5.1. Global Peptide and Oligonucleotide CDMO Market, by Research Institutes, By Region, 2019-2032 (USD Million)
  • 7.6. Academic and Government Organizations
    • 7.6.1. Global Peptide and Oligonucleotide CDMO Market, by Academic and Government Organizations, By Region, 2019-2032 (USD Million)
  • 7.7. Others
    • 7.7.1. Global Peptide and Oligonucleotide CDMO Market, by Others, By Region, 2019-2032 (USD Million)

8. Global Peptide and Oligonucleotide CDMO Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Peptide and Oligonucleotide CDMO Market Assessment, By Geography, 2019-2032 (USD Million)
  • 8.3. Peptide and Oligonucleotide CDMO Market - North America
    • 8.3.1. North America: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
    • 8.3.2. North America: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
    • 8.3.3. North America: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.3.4. Peptide and Oligonucleotide CDMO Market - U.S.
      • 8.3.4.1. U.S.: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.3.4.2. U.S.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.3.4.3. U.S.: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.3.5. Peptide and Oligonucleotide CDMO Market - Canada
      • 8.3.5.1. Canada: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.3.5.2. Canada.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.3.5.3. Canada: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • 8.4. Peptide and Oligonucleotide CDMO Market - Europe
    • 8.4.1. Europe: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
    • 8.4.2. Europe.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
    • 8.4.3. Europe: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.4.4. Peptide and Oligonucleotide CDMO Market - UK
      • 8.4.4.1. UK: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.4.4.2. UK.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.4.4.3. UK: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.4.5. Peptide and Oligonucleotide CDMO Market - France
      • 8.4.5.1. France: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.4.5.2. France.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.4.5.3. France: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.4.6. Peptide and Oligonucleotide CDMO Market - Germany
      • 8.4.6.1. Germany: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.4.6.2. Germany.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.4.6.3. Germany: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.4.7. Peptide and Oligonucleotide CDMO Market - Italy
      • 8.4.7.1. Italy: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.4.7.2. Italy.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.4.7.3. Italy: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.4.8. Peptide and Oligonucleotide CDMO Market - Spain
      • 8.4.8.1. Spain: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.4.8.2. Spain.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.4.8.3. Spain: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.4.9. Peptide and Oligonucleotide CDMO Market - Netherlands
      • 8.4.9.1. Netherlands: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.4.9.2. Netherlands.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.4.9.3. Netherlands: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.4.10. Peptide and Oligonucleotide CDMO Market - Russia
      • 8.4.10.1. Russia: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.4.10.2. Russia.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.4.10.3. Russia: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • 8.5. Peptide and Oligonucleotide CDMO Market - Asia Pacific
    • 8.5.1. Asia Pacific: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
    • 8.5.2. Asia Pacific.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
    • 8.5.3. Asia Pacific: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.5.4. Peptide and Oligonucleotide CDMO Market - China
      • 8.5.4.1. China: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.5.4.2. China.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.5.4.3. China: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.5.5. Peptide and Oligonucleotide CDMO Market - India
      • 8.5.5.1. India: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.5.5.2. India.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.5.5.3. India: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.5.6. Peptide and Oligonucleotide CDMO Market - Malaysia
      • 8.5.6.1. Malaysia: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.5.6.2. Malaysia.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.5.6.3. Malaysia: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.5.7. Peptide and Oligonucleotide CDMO Market - Japan
      • 8.5.7.1. Japan: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.5.7.2. Japan.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.5.7.3. Japan: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.5.8. Peptide and Oligonucleotide CDMO Market - Indonesia
      • 8.5.8.1. Indonesia: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.5.8.2. Indonesia.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.5.8.3. Indonesia: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.5.9. Peptide and Oligonucleotide CDMO Market - South Korea
      • 8.5.9.1. South Korea: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.5.9.2. South Korea.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.5.9.3. South Korea: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • 8.6. Peptide and Oligonucleotide CDMO Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
    • 8.6.2. Middle East & Africa.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
    • 8.6.3. Middle East & Africa: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.6.4. Peptide and Oligonucleotide CDMO Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.6.4.2. Saudi Arabia.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.6.4.3. Saudi Arabia: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.6.5. Peptide and Oligonucleotide CDMO Market - UAE
      • 8.6.5.1. UAE: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.6.5.2. UAE.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.6.5.3. UAE: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.6.6. Peptide and Oligonucleotide CDMO Market - Israel
      • 8.6.6.1. Israel: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.6.6.2. Israel.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.6.6.3. Israel: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.6.7. Peptide and Oligonucleotide CDMO Market - South Africa
      • 8.6.7.1. South Africa: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.6.7.2. South Africa.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.6.7.3. South Africa: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • 8.7. Peptide and Oligonucleotide CDMO Market - Latin America
    • 8.7.1. Latin America: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
    • 8.7.2. Latin America.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
    • 8.7.3. Latin America: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.7.4. Peptide and Oligonucleotide CDMO Market - Mexico
      • 8.7.4.1. Mexico: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.7.4.2. Mexico.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.7.4.3. Mexico: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.7.5. Peptide and Oligonucleotide CDMO Market - Brazil
      • 8.7.5.1. Brazil: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.7.5.2. Brazil.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.7.5.3. Brazil: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.7.6. Peptide and Oligonucleotide CDMO Market - Argentina
      • 8.7.6.1. Argentina: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.7.6.2. Argentina.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.7.6.3. Argentina: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Aurigene Pharmaceutical Services Ltd.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Bachem Group
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. CordenPharma
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Creative Peptides
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Curia Global, Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. EUROAPI
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Genscript Biotech Corporation
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Lonza Group
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Merck KGaA
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. PolyPeptide Group
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Senn Chemicals AG
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. STA Pharmaceutical Co. Ltd.
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Sylentis, S.A.
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Thermo Fisher Scientific Inc.
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Benchmarking
    • 10.14.4. Recent Development
  • 10.15. Wuxi AppTec
    • 10.15.1. Company Overview
    • 10.15.2. Financial Performance
    • 10.15.3. Product Benchmarking
    • 10.15.4. Recent Development

List of Tables

  • Table 1 Global Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 2 Global Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 3 Global Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 4 Peptide and Oligonucleotide CDMO Market Assessment, By Geography, 2019-2032 (USD Million)
  • Table 5 North America: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 6 North America: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 7 North America: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 8 U.S.: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 9 U.S.: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 10 U.S.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 11 Canada: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 12 Canada: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 13 Canada: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 14 Europe: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 15 Europe: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 16 Europe: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 17 UK: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 18 UK: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 19 UK: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 20 France: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 21 France: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 22 France: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 23 Germany: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 24 Germany: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 25 Germany: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 26 Italy: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 27 Italy: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 28 Italy: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 29 Spain: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 30 Spain: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 31 Spain: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 32 Netherlands: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 33 Netherlands: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 34 Netherlands: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 35 Russia: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 36 Russia: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 37 Russia: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 38 Asia Pacific: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 39 Asia Pacific: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 40 Asia Pacific: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 41 China: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 42 China: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 43 China: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 44 India: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 45 India: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 46 India: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 47 Malaysia: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 48 Malaysia: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 49 Malaysia: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 50 Japan: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 51 Japan: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 52 Japan: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 53 Indonesia: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 54 Indonesia: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 55 Indonesia: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 56 South Korea: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 57 South Korea: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 58 South Korea: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 59 Middle East & Africa: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 60 Middle East & Africa: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 61 Middle East & Africa: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 62 Saudi Arabia: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 63 Saudi Arabia: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 64 Saudi Arabia: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 65 UAE: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 66 UAE: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 67 UAE: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 68 Israel: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 69 Israel: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 70 Israel: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 71 South Africa: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 72 South Africa: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 73 South Africa: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 74 Latin America: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 75 Latin America: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 76 Latin America: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 77 Mexico: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 78 Mexico: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 79 Mexico: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 80 Brazil: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 81 Brazil: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 82 Brazil: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 83 Argentina: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 84 Argentina: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 85 Argentina: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)

List of Figures

  • Figure 1. Global Peptide and Oligonucleotide CDMO Market, 2019-2032 (USD Million)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Service
  • Figure 7. Global Peptide and Oligonucleotide CDMO Market, by Service, 2022 & 2032 (USD Million)
  • Figure 8. Market by Product
  • Figure 9. Global Peptide and Oligonucleotide CDMO Market, by Product, 2022 & 2032 (USD Million)
  • Figure 10. Market by End User
  • Figure 11. Global Peptide and Oligonucleotide CDMO Market, by End User, 2022 & 2032 (USD Million)
  • Figure 12. Peptide and Oligonucleotide CDMO Market Assessment, By Geography, 2019-2032 (USD Million)
  • Figure 13. Strategic Analysis - Peptide and Oligonucleotide CDMO Market